

31 **ABSTRACT**

32

33 Genomic amplification of the distal portion of chromosome 3q, which encodes a number of oncogenic
34 proteins, is one of the most frequent chromosomal abnormalities in malignancy. Here we functionally
35 characterise a non-protein product of the 3q region, the long noncoding RNA (lncRNA) PLANE, which
36 is upregulated in diverse cancer types through copy number gain as well as E2F1-mediated
37 transcriptional activation. PLANE forms an RNA-RNA duplex with the nuclear receptor co-repressor 2
38 (NCOR2) pre-mRNA at intron 45, binds to heterogeneous ribonucleoprotein M (hnRNPM) and
39 facilitates the association of hnRNPM with the intron, thus leading to repression of the alternative
40 splicing (AS) event generating NCOR2-202, a major protein-coding NCOR2 AS variant. In
41 consequence, PLANE promotes cancer cell proliferation and tumorigenicity and its upregulation is
42 associated with poor patient outcomes. These results uncover the function and regulation of PLANE and
43 suggest that PLANE may constitute a therapeutic target in the pan-cancer context.

44

45

46

47

48 INTRODUCTION

49
50 Alternative splicing (AS) of precursor mRNAs (pre-mRNAs) is a fundamental mechanism that allows
51 for the generation of diverse mature transcripts from a single gene thus amplifying the gene-coding
52 capacity and increasing the functional diversity^{1,2,3}. Over 95% of human multiexon genes undergo AS
53 that is tightly controlled by the interaction of trans-acting proteins referred to as splicing factors with
54 cis-acting nucleotide sequences^{1,2,3}. Splicing factors encompass members of the serine-arginine (SR)
55 protein family and heterogeneous ribonucleoproteins (hnRNPs) that promote or repress specific splicing
56 events through interacting with exonic or intronic regulatory sequences classified as enhancers or
57 silencers^{1,4}. Aberrant AS events are involved in the pathogenesis of many diseases including cancer
58 through deregulating essential cellular processes such as cell survival and proliferation^{1,4,5,6}.

59
60 Nuclear receptor co-repressor 2 (NCOR2), also known as silencing mediator of retinoid and thyroid
61 hormone receptors (SMRT) or T₃ receptor-associating cofactor 1 (TRAC-1), acts as a central organising
62 platform for assembling functional complexes which repress the transactivation of target genes. The
63 NCOR2 N-terminal repression domains recruit other transcriptional corepressors such as histone
64 deacetylases (HDACs) while its C-terminal interaction domains interact with nuclear receptors such as
65 the thyroid hormone receptor and retinoic acid receptor^{7,8,9}. Moreover, NCOR2-mediated repression
66 also targets genes activated by other transcription factors such as AP-1 and NF- κ B^{9,10,11}. With its
67 repression domains retained, NCOR2 exhibits varying affinities for different transcription factors
68 through AS at its C-terminus^{9,12,13}. Of note, cancer cells often display altered expression of NCOR2,
69 implicating a role of its deregulation in cancer pathogenesis^{14,15,16,17,18}. For example, NCOR2 is
70 downregulated in multiple myeloma and its low expression is associated the development of non-
71 Hodgkin's lymphoma and poor prognosis of lung adenocarcinoma (LUAD) patients^{14,15,16,17}. In contrast,
72 high NCOR2 expression is linked to earlier recurrence of breast carcinoma (BRCA)¹⁸.

73
74 There is increasing appreciation of the role of long noncoding RNAs (lncRNAs) in cancer development
75 and progression^{1,19,20,21,22}. In particular, a growing number of lncRNAs have been linked to the
76 deregulation of AS in cancer cells^{23,24,25,26,27,28}. lncRNAs regulate AS primarily through binding to

77 splicing factors, associating with pre-mRNAs and impinging on chromatin remodelling²⁴. For instance,
78 the lncRNA MALAT1 regulates alternative splicing of a set of pre-mRNAs through modulating SR
79 splicing factor phosphorylation and sub-nuclear localization, and is thus involved in the development,
80 progression and treatment resistance of many types of cancers²⁶, whereas the lncRNA LNIC01133
81 interacts with the SR splicing factor SRSF6 (SRp55) resulting in inhibition of epithelial-mesenchymal
82 transition (EMT) and metastasis²⁷. Moreover, the lncRNA SAF binds to the *Fas* pre-mRNA and recruits
83 splicing factor 45 (SPF45) leading to generation of a Fas AS variant that protects cancer cells from Fas-
84 induced cell death²⁸.

85
86 Here we present evidence that the lncRNA PLANE forms an RNA-RNA duplex with the NCOR2 pre-
87 mRNA and recruits hnRNPM, thus facilitating hnRNPM-mediated repression of the AS event
88 generating NCOR2-202, a major protein-coding NCOR2 transcript variant. The resulting
89 downregulation of NCOR2 at the protein level contributes to the increased proliferation and
90 tumorigenicity of cancer cells. Moreover, we show that PLANE is frequently upregulated in diverse
91 cancer types through genomic amplification and E2F1-mediated transcriptional activation, with
92 practical implications of interference with PLANE as potential treatment approach in the pan-cancer
93 context.

94 **RESULTS**

95

96

97

Genomic amplification and transcriptional activation by E2F1 drive PLANE upregulation in

98 **diverse cancer types**

99

100 Through interrogating the lncRNA expression data in the Cancer Genome Atlas (TCGA)²⁹, we identified

101 a panel of eighteen pan-cancer upregulated lncRNAs that were increased in expression in at least 19 of

102 20 cancer types in relation to corresponding normal tissues ([Supplementary Fig. 1a](#)). Among them was

103 melanotransferrin (MELTF, also known as MFI2) antisense RNA1 (MELTF-AS1 or MFI2-AS1) that is

104 encoded by a gene located to the distal portion of chromosome 3q (3q29) ([Supplementary Fig. 1a-c](#)),

105 whose amplification is one of the most prevalent chromosomal abnormalities observed in various cancer

106 types^{30, 31, 32, 33, 34}. Indeed, *MELTF-AS1* was the most frequently amplified gene among those that encode

107 the pan-cancer upregulated lncRNAs ([Supplementary Fig. 1d](#)). We therefore sought to investigate the

108 potential role of MELTF-AS1 in cancer pathogenesis. Of the five annotated MELTF-AS1 isoforms

109 (Vega Genome Browser), the longest isoform was markedly more abundant than others in multiple

110 cancer cell lines, including A549 and H1299 LUAD, NCI-H226 lung squamous cell carcinoma (LUSC),

111 HCT116 colon adenocarcinoma (COAD), MCF-7 BRCA and Eca109 esophageal squamous carcinoma

112 (ESCC) ([Supplementary Fig. 1e, f](#)). We hereafter focused on this isoform and renamed it PLANE (Pan-

113 cancer LncRNA Activating NCOR2 responsive to E2F1) given its functional relationship with NCOR2

114 and transcriptional responsiveness to E2F1 (see below). PLANE consists of 4 exons (E1-E4), with

115 minimum free energy modelling predicting a broadly symmetrical structure with E1 and E3 constituting

116 each pole, whereas E2 and E4 contributing to both poles of the molecule ([Supplementary Fig. 1g](#)).

117

118 We confirmed the cancer-associated upregulation of PLANE in cohorts of formalin-fixed paraffin-

119 embedded (FFPE) LUSC, LUAD and COAD samples compared to paired adjacent normal tissues ([Fig.](#)

120 [1a](#)). Noticeably, despite the common increase in cancer tissues, PLANE levels did not differ among

121 tumours of different stages ([Supplementary Fig. 2a & Supplementary Tables 1-3](#)). Likewise, there were

122 no significant differences in PLANE expression between LUSC, LUAD and COAD of different groups

123 stratified by tumour grade and patient gender as well as their median age at diagnosis ([Supplementary](#)

124 [Tables 1-3](#)). Moreover, no significant changes were found in PLANE expression levels between COAD
125 and colon adenomas (pre-neoplastic colon lesions), whereas PLANE expression was increased in colon
126 adenomas compared with normal colon epithelia ([Supplementary Fig. 2b](#)). Collectively, these results
127 suggest that PLANE upregulation is an early event during tumorigenesis. Furthermore, high PLANE
128 expression was associated with poorer overall patient survival (OS) in diverse cancer types ([Fig. 1b &](#)
129 [Supplementary Fig. 2c](#)), implicating its broad involvement in cancer development and progression.

130
131 Consistent with the contribution of genomic amplification to the upregulation of PLANE in some cancer
132 tissues ([Supplementary Fig. 1d](#)), qPCR analysis of genomic DNA demonstrated *PLANE* copy number
133 gains in ~36% of LUSC (8 of 22) and ~4% of LUAD (1 of 24) ([Fig. 1c](#)). Increases in *PLANE* copy
134 numbers were also evident in 2 of 7 cancer cell lines compared with the CCC-HIE-2 normal human
135 intestinal epithelial cell line ([Fig. 1d](#)). Nonetheless, similar to the pan cancer upregulation of PLANE in
136 tissue samples, all the cancer cell lines examined expressed higher levels of PLANE than the CCC-HSF-
137 1 normal skin fibroblast cell line irrespective of their amplification status ([Supplementary Fig. 2d](#)),
138 indicating that additional causal mechanisms such as transcriptional regulation is involved in the
139 upregulation of PLANE in cancer cells. In support, absolute quantitation showed that there were
140 respectively ~157 and ~262 PLANE molecules per A549 and H1299 cell, which did not have copy
141 number gains in the *PLANE* gene, compared with ~20 PLANE molecules per CCC-HSF-1 cell ([Fig. 1e](#)).

142
143 To gain insights into transcriptional mechanisms involved in PLANE upregulation in cancer cells, we
144 analysed its promoter for transcription factor binding sites using bioinformatics. This predicted multiple
145 E2F1-binding motifs located to the -314/-14 region of the proximal promoter of the *PLANE* gene
146 ([Supplementary Fig. 3a](#))³⁵. Indeed, this region (E2F1-BR) was co-precipitated with endogenous E2F1
147 and was required for transcriptional upregulation of PLANE as the transcriptional activity of a *PLANE*
148 reporter construct was inhibited when the E2F1-BR was deleted ([Fig. 1f, g](#)). Moreover, co-transfection
149 of E2F1 selectively enhanced the transcriptional activity of the *PLANE* reporter whereas knockdown of
150 E2F1 diminished reporter activity ([Supplementary Fig. 3b, c](#)), supporting the notion that *PLANE* is
151 transcriptionally activated by E2F1 through the identified E2F1-BR. In accordance, knockdown of E2F1
152 reduced the endogenous PLANE levels, whereas overexpression of E2F1 caused PLANE upregulation

153 (Fig. 1h & Supplementary Fig. 3d). Furthermore, PLANE levels were correlated with E2F1 expression
154 levels in diverse cancer types (Supplementary Fig. 3e). Collectively, these results demonstrate that E2F1
155 along with genomic amplification are responsible for the upregulation of PLANE in cancer cells.

156
157 The gene encoding PLANE is divergently located opposite to the protein-coding gene *MELTF*
158 (Supplementary Fig. 4a). Nevertheless, knockdown of PLANE did not impinge upon MELTF
159 expression (Supplementary Fig. 4b), and similarly, knockdown of MELTF did not affect PLANE
160 expression levels (Supplementary Fig. 4c). Thus, there is no regulatory interaction between PLANE and
161 its neighbouring gene *MELTF*.

162 163 **PLANE promotes cancer cell proliferation and tumorigenicity**

164
165 We examined the biological significance of PLANE upregulation in cancer cells. SiRNA knockdown of
166 PLANE inhibited cell proliferation and reduced clonogenicity in diverse cancer cell lines (Fig. 2a-c),
167 which was associated with G0/G1 cell cycle arrest (Supplementary Fig. 5a). Conversely, overexpression
168 of PLANE increased, albeit moderately, proliferation in A549 and H1299 cells (Supplementary Fig. 5b).
169 Gene set enrichment analysis (GSEA) of the RNA-sequencing (RNA-seq) data from A549 cells revealed
170 that knockdown of PLANE caused downregulation of numerous genes of signalling pathways involved
171 in cell cycle progression, including the E2F1, G2/M checkpoint and mitotic spindle assembly pathways
172 (Supplementary Fig. 5c). Thus, PLANE expression promotes the integral proliferative machinery of
173 cancer cells.

174
175 To facilitate further investigations, we established A549 and H1299 sublines (A549.shPLANE and
176 H1299.shPLANE) with conditional knockdown of PLANE in response to doxycycline (Dox) (Fig. 2d).
177 Induced PLANE knockdown similarly triggered reductions in cell proliferation and clonogenicity and
178 induced anchorage-independent growth in A549.shPLANE and H1299.shPLANE sublines (Fig. 2e-g).
179 Moreover, Dox treatment of nu/nu mice retarded the growth of A549.shPLANE.1 xenografts (Fig. 2h, i
180 & Supplementary Fig. 5d, e). Cessation of Dox treatment restored the expression of PLANE and
181 recovered, at least in part, the clonogenic potential *in vitro* and tumour xenograft growth in mice (Fig.
182 2h, i & Supplementary Fig. 5d, e), further consolidating the role of PLANE in tumorigenicity.

183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211

PLANE regulates NCOR2 pre-mRNA AS

To dissect the mechanisms whereby PLANE promotes cancer cell proliferation, we compared the transcriptomes of A549 cells with and without PLANE knockdown. The results showed that the NCOR2 AS variant, NCOR2-202 (ENST00000397355.1; grch37.ensembl.org), was the most highly upregulated transcript associated with knockdown of PLANE (Fig. 3a). Interestingly, there were no significant changes in the levels of other protein-coding NCOR2 AS variants, including NCOR2-001 and NCOR2-005, which along with NCOR2-202, give rise to the three major NCOR2 protein isoforms, NCOR2-3, -1 and -2, respectively (Fig. 3a & Supplementary Fig. 6a)³⁶. Due to sequence overlaps it was not feasible to specifically confirm the increase in the NCOR2-202 AS variant using qPCR (Supplementary Fig. 6a), but analysis using primers recognising a common region present in NCOR2-001, NCOR2-202 and NCOR2-005 demonstrated increased expression following PLANE knockdown (Fig. 3b & Supplementary Fig. 6a), conceivably reflecting NCOR2-202 upregulation. Furthermore, immunoblotting with NCOR2 antibodies against residues near its N-terminus that are conserved in NCOR2 protein isoforms 1-3 demonstrated that knockdown of PLANE caused an increase in NCOR2 protein expression (Fig. 3b & Supplementary Fig. 6a), suggesting that the increase in the NCOR2-202 AS variant was translated to the upregulation of the NCOR2 protein. Consistently, overexpression of PLANE caused downregulation of NCOR2 protein levels (Fig. 3c).

To verify that the upregulation of the NCOR2-202 AS variant caused by PLANE knockdown was due to a posttranscriptional increase, we tested the levels of the NCOR2 pre-mRNA in cells with and without knockdown of PLANE. The results showed that PLANE knockdown did not alter NCOR2 pre-mRNA expression (Supplementary Fig. 6b). Similarly, overexpression of PLANE did not cause any changes in NCOR2 pre-mRNA levels (Supplementary Fig. 6c). Moreover, knockdown of PLANE did not affect the enrichment of the transcriptional activation mark H3K4me3 and the transcriptional repression mark H3K27me3 to the *PLANE* promoter (Supplementary Fig. 6d)³⁷. Collectively, these results point to posttranscriptional regulation of NCOR2 expression by PLANE through controlling the AS event generating the NCOR2-202 transcript. To substantiate this, we carried out semiquantitative RT-PCR

212 analysis using primers flanking the splice site at the junction of exon/intron 45 which generates NCOR2-
213 202. Detection of the splicing event generating NCOR2-001 and NCOR2-005 at the junction was
214 included as a control. Here NCOR2-202 differs from NCOR2-001 and NCOR2-005 in its generation
215 through an alternative 5' splice site ([Supplementary Figs. 6a & 7a](#)). Instructively, PLANE knockdown
216 resulted in an increase in the NCOR2-202-generating AS event but did not affect the event giving rise
217 to NCOR2-001/NCOR2-005 ([Fig. 3d, e](#)). In contrast, overexpression of PLANE reduced the NCOR2-
218 202-generating AS event ([Fig. 3f, g](#)). Thus, PLANE represses the AS event that produces NCOR2-202.

219
220 To investigate the biological impact of PLANE regulation of AS production of NCOR2-202, we tested
221 the effect of siRNAs targeting common regions of NCOR2-001, NCOR2-005 and NCOR2-202 on
222 inhibition of cell proliferation caused by PLANE knockdown ([Supplementary Fig. 6a](#)), which
223 conceivably reflected the consequence of inhibition NCOR2-202 expression, as NCOR2 protein
224 upregulation in PLANE knockdown cells was exclusively caused by the increase in NCOR2-202 ([Fig.](#)
225 [3a, b & Supplementary Fig. 6a](#)). For simplicity, we hereafter refer to these siRNAs as NCOR2 siRNAs.
226 As anticipated, introduction of the NCOR2 siRNAs diminished the upregulation of NCOR2 and
227 reversed, at least partially, the reduction in cell proliferation and clonogenicity caused by knockdown of
228 PLANE ([Fig. 3h, i & Supplementary Fig. 7b](#)). Of note, NCOR2 knockdown alone caused moderate
229 increases in cell proliferation ([Fig. 3h, i & Supplementary Fig. 7b](#)).

230
231 We also tested whether PLANE impinges on AS of other pre-mRNAs through analysing RNA-seq data
232 from A549 cells using the modelling alternative junction inclusion quantification (MAJIQ) that detects
233 and quantifies local splicing variations (LSVs), including classical binary splicing events and non-
234 classical binary splits and splits involving more than two junctions³⁸. MAJIQ analysis identified 46916
235 and 48635 AS events across 10187 genes in cells with and without PLANE knockdown, respectively,
236 with 55 significant LSVs apart from the NCOR2-202-generating splicing event triggered by knockdown
237 of PLANE ($\Delta \text{PSI} \geq 20\%$; confidence threshold $>95\%$) ([Fig. 3j](#)). By use of semiquantitative RT-PCR
238 we validated 5 randomly selected LSVs caused by knockdown of PLANE ([Fig. 3k](#)). Together, these
239 results demonstrate that PLANE regulates AS of many other pre-mRNAs in addition to NCOR2,

240 although its role in promoting cell proliferation is largely attributable to its modulatory effects on
241 NCOR2 pre-mRNA AS.

242
243 **PLANE forms an RNA-RNA duplex with the NCOR2 pre-mRNA**

244
245 PLANE predominantly localized to the nucleus as shown by ISH analysis of A549 cells grown on
246 coverslips and qPCR analysis of subcellular fractions (Fig. 4a, b), suggesting the possibility through
247 forming RNA-RNA duplexes with pre-mRNAs to regulate AS. Bioinformatics analysis using the
248 IntaRNA program (<http://rna.informatik.uni-freiburg.de>) identified a potential PLANE-binding region
249 (PLANE-BR) at intron 45 of the NCOR2 pre-mRNA that complements to a fragment enriched of
250 duplex-forming oligonucleotides (DFOs) contained in PLANE (Supplementary Fig. 7c)³⁹. To test
251 whether PLANE forms RNA-RNA duplexes with the NCOR2 pre-mRNA, we employed a cell-free
252 assay system. In vitro-synthesized biotin-labelled PLANE precipitated an RNA fragment containing
253 the PLANE-BR at intron 45 of the NCOR2 pre-mRNA (Fig. 4c). However, this association was
254 diminished when the PLANE-BR or the DFOs within PLANE were deleted (Fig. 4c). Moreover, biotin-
255 labelled PLANE failed to precipitate a fragment of the NCOR2 pre-mRNA that did not contain the
256 PLANE-BR (Fig. 4d). Consistently, in vitro-synthesized biotin-labelled PLANE also precipitated the
257 NCOR2 pre-mRNA from A549 and H1299 cell nuclear extracts (Fig. 4e). In addition, endogenous
258 PLANE bound to the PLANE-BR but not a non-PLANE-BR-containing fragment of endogenous
259 NCOR2 pre-mRNA as shown in domain-specific chromatin isolation by RNA purification (dChIRP)
260 assays (Fig. 4f). Collectively, these results reveal the formation of an RNA-RNA duplex between
261 PLANE and the NCOR2 prem-mRNA through the DFOs and PLANE-BR, respectively. Of note,
262 treatment of nuclear extracts from A549 cells with proteinase K did not disrupt the RNA-RNA duplex
263 formed by PLANE and the NCOR2 pre-mRNA (Fig. 4g), demonstrating the binding between PLANE
264 and the NCOR2 pre-mRNA is direct and not protein dependent.

265
266 We then examined the functional significance of the RNA-RNA duplex in PLANE-mediated regulation
267 of NCOR2 pre-mRNA AS and cell proliferation. In contrast to overexpression of wild-type PLANE
268 (Fig. 3f, g & Supplementary Fig. 5b), introduction of a PLANE mutant lacking the DFOs into A549 and

269 H1299 cells had no effect on the NCOR2-202-generating splicing event and cell proliferation (Fig. 4h,
270 i & Supplementary Fig. 7d). Moreover, introduction of a shRNA-resistant PLANE mutant (PLANE-R)
271 inhibited the AS event caused by PLANE knockdown (Fig. 4j, k). Taken together with preceding data
272 (Fig. 4c-k & Supplementary Fig. 7d), these findings indicate that the formation of the RNA-RNA duplex
273 is required for the PLANE effects on NCOR2 pre-mRNA AS and cell proliferation.

274 275 **PLANE interacts with hnRNPM**

276
277 We also interrogated the proteins that interact with PLANE using RNA-pulldown followed by mass
278 spectrometry. The most abundant protein that coprecipitated with PLANE was hnRNPM (Fig. 5a &
279 Supplementary Table 4), one of the hnRNP proteins that complex with heterogeneous nuclear RNA and
280 are essential in regulating mRNA maturation processes including pre-mRNA splicing^{40, 41}. The
281 association between PLANE and hnRNPM was readily confirmed using RNA pulldown and RNA
282 immunoprecipitation (RIP) assays (Fig. 5b, c). In contrast, no association was detected between PLANE
283 and hnRNPK that was included as a control (Fig. 5b). Similarly, there was no association between
284 hnRNPM and the mitochondrial lncRNA lncCyt b included as an additional control (Fig. 5c). In support
285 of the direct interaction between PLANE and hnRNPM, *in vitro*-synthesized PLANE co-precipitated
286 recombinant hnRNPM in a cell free system (Fig. 5d).

287
288 To define the region of PLANE responsible for its interaction with hnRNPM, we carried out mapping
289 experiments with PLANE mutants transcribed *in vitro* (Supplementary Fig. 8a). This analysis showed
290 that PLANE fragment 331-751 but not fragment 1-330 or 752-951 was coprecipitated with hnRNPM
291 (Fig. 5e), indicating that the 331-751 region of PLANE is required for its association with hnRNPM.
292 We also conducted mapping experiments to identify the structural determinant for the binding of
293 hnRNPM with PLANE. hnRNPM contains three RNA recognition motifs (RRMs) that are located at aa
294 72-147, aa 206-279, and aa 654-730, respectively (Supplementary Fig. 8b). Deletion of the aa 206-279
295 RRM but not the aa 72-147 or aa 206-279 RRM diminished the association between hnRNPM and
296 PLANE (Fig. 5f), indicating that the aa 206-279 RRM of hnRNPM is necessary for its binding to
297 PLANE.

298

299 **PLANE links hnRNPM to regulation of NCOR2 pre-mRNA AS**

300

301 We next investigated the relationship of PLANE and hnRNPM in regulating NCOR2 pre-mRNA AS.

302 As anticipated, hnRNPM predominantly localised to the nucleus in A549 and H1299 cells

303 (Supplementary Fig. 8c). Noticeably, while a proportion of hnRNPM colocalized with the splicing

304 factor SC35, a marker of nuclear speckles where the pre-mRNA splicing machinery is assembled,

305 modified and stored (Fig. 5g)⁴², hnRNPM was also co-precipitated with U1 small nuclear

306 ribonucleoprotein 70kDa (snRNP70; as known as U1-70K) that associates with the spliceosome small

307 nuclear RNA (snRNA) U1 and is commonly used as a marker of spliceosomes (Fig. 5h)^{25, 43}, consistent

308 with its role as a splicing factor.

309

310 Through in silico analysis we identified a fragment enriched of consensus hnRNPM-binding sites

311 (hnRNPM-BSs) within intron 45 of the NCOR2 pre-mRNA (Supplementary Fig. 8d). Indeed, hnRNPM

312 bound to the fragment as demonstrated in RNA pulldown and RIP assays (Fig. 6a, b). Instructively,

313 knockdown of hnRNPM enhanced the NCOR2-202 generating AS event (Fig. 6c, d), recapitulating the

314 effect of knockdown of PLANE (Fig. 3d, e), whereas hnRNPM overexpression reduced the AS event,

315 which was however diminished by PLANE knockdown (Fig. 6e, f), suggesting that hnRNPM is involved

316 in PLANE-mediated regulation of NCOR2 pre-mRNA AS. In support, knockdown of PLANE reduced

317 the amount of hnRNPM associated with the NCOR2 pre-mRNA (Fig. 6g), indicating that PLANE is

318 necessary for the binding between hnRNPM and the pre-mRNA. In contrast, knockdown of hnRNPM

319 did not affect the association between PLANE and the NCOR2 pre-mRNA (Fig. 6h), demonstrating that

320 the interaction between PLANE and the pre-mRNA does not require hnRNPM. Consolidating the role

321 of PLANE in the interaction between hnRNPM and the hnRNPM-BSs, restoration of the NCOR2-202

322 generating AS event by introduction of PLANE-R into cells with endogenous PLANE knockdown was

323 associated with reinstatement of the association between hnRNPM and the hnRNPM-BSs (Figs. 4j, k &

324 6g). However, introduction of a PLANE mutant with the 331-751 fragment deleted to disrupt its

325 interaction with hnRNPM or with its DFOs deleted to interfere with its interaction with the NCOR2 pre-

326 mRNA did not restore the hnRNPM-hnRNPM-BS association (Fig. 6i). Collectively, these results

327 indicate that PLANE facilitates the binding of hnRNPM with the NCOR2 pre-mRNA and is necessary
328 for hnRNPM-mediated regulation of NCOR2 pre-mRNA AS.

329 **DISCUSSION**

330
331 A number of proteins encoded by genes located to the distal portion of chromosome 3q that is frequently
332 amplified in various cancer types are known to drive cancer pathogenesis, such as the p110 α subunit of
333 phosphatidylinositol 3-kinase (PI3K α) and eukaryotic translation initiation factor 4 G (eIF4G)^{44, 45}. In
334 this study, we demonstrate that PLANE, a lncRNA encoded by a gene situated in this region, is similarly
335 upregulated in diverse cancer types and promotes cancer cell proliferation and tumorigenicity, thus
336 uncovering a hitherto unrecognised oncogenic contribution of a non-protein coding component of the
337 distal portion of chromosome 3q. Nevertheless, genomic amplification is not the only mechanism
338 responsible for the increased PLANE expression in cancer cells, rather, PLANE upregulation is more
339 commonly driven by E2F1-mediated transcriptional activation. As a transcription factor with
340 dichotomous functions, E2F1 on one hand transactivates many protein-coding genes involved in cell
341 cycle progression and its high expression causes tumorigenesis^{46, 47}, but on the other hand, E2F1 loss
342 has also been demonstrated to induce cancer development and progression⁴⁸. Our results identified
343 transcriptional activation of PLANE as a mechanism involved in E2F1 promotion of cell proliferation,
344 suggesting that PLANE may represent a potential target for counteracting the cancer-promoting axis of
345 E2F1 signalling.

346
347 PLANE promoted cancer cell proliferation and tumorigenicity through inhibition of the expression of
348 NCOR2, which, as a transcriptional corepressor, functions by way of a platform that links chromatin
349 modifying enzymes such as HDACs and transcription factors to regulate transactivation of downstream
350 genes involved in many cellular processes including cell survival and proliferation^{9, 10, 11}. As such,
351 deregulation of NCOR2 is associated the pathogenesis of various diseases including cancer^{14, 15, 16, 17, 18}.
352 In support of our results, a number of studies have demonstrated a tumour suppressive role of NCOR2
353 in cancers, such as LUAD, head and neck squamous cell carcinoma, non-Hodgkin lymphoma and
354 osteosarcoma^{14, 15, 16, 17}. However, NCOR2 has also been shown to promote cell survival and proliferation
355 in some other cancer types such as breast cancer¹⁸, suggestive of an oncogenic role. These paradoxical
356 observations are nevertheless consistent with the notion that NCOR2 functions in a manner closely
357 related to the diverse repertoire of NCOR2 isoforms generated by AS at its C-terminal interaction

358 domains resulting in varying affinities for different transcription factors^{9, 12, 13}. Indeed, we found that
359 PLANE-mediated suppression of NCOR2 expression was due to selective repression of AS production
360 of the NCOR2-202 transcript that encodes one of the major NCOR2 protein isoforms, NCOR2 isoform
361 2³⁶, demonstrating a tumour suppressive function of this isoform. Nonetheless, whether each of the other
362 NCOR2 isoforms has any specific effect on cancer pathogenesis remains to be defined. The expression
363 of the NCOR2 isoform BQ323636.1 is known to confer chemoresistance in breast cancer⁴⁹. Moreover,
364 the NCOR2 pre-mRNA splicing pattern may change in a context-dependent fashion as it does during
365 adipocyte differentiation⁵⁰.

366
367 Mechanistic investigations revealed that the formation of an RNA-RNA duplex was necessary for
368 PLANE to repress the AS event generating NCOR2-202, acting through the DFOs within PLANE and
369 the complementary PLANE-BR at intron 45 of NCOR2 pre-mRNA. The nature of the duplex interaction
370 was substantiated through several independent experimental approaches and importantly it was
371 demonstrated that disruption of the duplex was sufficient to abolish the repression of the NCOR2-202-
372 generating AS event and inhibition of cell proliferation. A number of lncRNAs have been shown to
373 regulate AS through forming RNA-RNA duplexes with pre-mRNAs and thus regulate gene expression
374 through modification of the transcript landscape^{24, 28, 51}. This is commonly accomplished through
375 targeting particular splicing factors by lncRNA to selective cis-acting nucleotide sequences²⁴. For
376 example, the lncRNA SAF complexes with the Fas pre-mRNA at the exon 5-6 and exon 6-7 junction
377 and binds to SPF45, thus facilitating exclusion of exon 6 leading to the generation of a Fas protein
378 isoform that lacks the transmembrane domain and cannot induce apoptosis²⁸. Moreover, the lncRNA
379 zinc finger E-box binding homeobox 2 (ZEB2) antisense RNA 1 (ZEB2-AS1) forms RNA-RNA duplex
380 with the ZEB2 pre-mRNA and thus prevents the recognition of the spliceosome resulting in intron
381 inclusion at the ZEB 5'-UTR and consequent promotion of ZEB2 translation, activating EMT⁵¹.
382 Similarly, the RNA-RNA duplex formed by PLANE and the NCOR2 pre-mRNA functions to facilitate
383 the association of hnRNPM with intron 45 of the pre-mRNA leading to suppression of the NCOR2-202
384 generating AS event. Noticeably, PLANE was also found to regulate many other AS events, although
385 the biological consequences remain to be defined. Similarly, the mechanisms regulating the formation

386 of RNA-RNA duplex between PLANE and selective pre-mRNAs remain to be determined. Regardless,
387 our results clearly demonstrated that the effect of PLANE on cancer cell proliferation is largely due to
388 its regulation of the NCOR2-202-generating AS event through forming an RNA-RNA duplex with the
389 NCOR2 pre-mRNA.

390
391 Like other hnRNP family proteins, hnRNPM is involved in regulating RNA maturation processes^{40, 41}.
392 In particular, it controls AS of a variety of pre-mRNAs of cancer-associated genes^{40, 52, 53, 54}. For instance,
393 hnRNPM mediates AS of fibroblast growth factor receptor 2 (FGFR2) and CD44 pre-mRNAs to
394 promote EMT^{52, 53, 54}. Moreover, hnRNPM guides an AS program involving multiple pre-mRNAs to
395 confer resistance of Ewing sarcoma cells to inhibition of the PI3K/AKT/mTOR signal pathway²⁵.
396 Consistent with these cancer-promoting actions, our results showed that hnRNPM along with PLANE
397 represses the AS event generating NCOR2-202 and thus promotes cancer cell proliferation. Although
398 hnRNPs commonly act as splice suppressors when binding to exonic motifs, and as splicing enhancers
399 when associating with motifs in introns^{55, 56}, its binding to the hnRNPM-BSs at intron 45 of the NCOR2
400 pre-mRNA results in suppression of the NCOR2-202-generating AS event, suggesting that hnRNPM
401 can function as an AS suppressor when it binds to intronic regulatory sequences. The finding that
402 PLANE links hnRNPM to repress the NCOR2-202-generating AS event indicates that PLANE
403 determines the selectivity of hnRNPM on the splice site of the NCOR2 pre-mRNA. Indeed, there is
404 increasing evidence showing that lncRNAs can function as “local address codes” to target regulatory
405 proteins to nucleotide sequences³⁷.

406
407 The hnRNPM protein is highly abundant in cells^{25, 57}. A previous quantitative proteomic study in U2OS
408 cells showed that hnRNPM was present with >1,400,000 molecules⁵⁷. On the other hand, PLANE is
409 expressed at markedly lower abundance, approximately 157 to 262 molecules per A549 and H1299
410 cells. A question arising from this disparity is whether the limited numbers of PLANE molecules are
411 sufficient to link enough hnRNPM necessary for repressing the NCOR2-202-generating AS event.
412 Nevertheless, the function of hnRNPM as a splice factor is tightly regulated by its posttranslational
413 modifications, for example, phosphorylation and sub-nuclear translocation⁴¹. Indeed, the vast majority
414 of hnRNPM was found to locate to the nuclear speckles, where the pre-mRNA splicing machinery is

415 assembled, modified and stored⁴², whereas the execution of a specific AS event is highly dynamic and
416 conceivably requires limited resources from the general splicing machinery⁴². Thus, the factual
417 difference between the number of PLANE copies and the number of hnRNPM molecules is conceivably
418 not as large as estimated at the face value. Regardless, that PLANE links hnRNPM to repression of the
419 NCOR2-202-generating AS is not in dispute since the process can be modelled *in vitro* and the action
420 is sufficient to suppress cancer cell survival tumorigenicity.

421
422 One of the features of lncRNAs compared to protein-coding genes is their relatively poor sequence
423 conservation^{29, 37}. By use of bioinformatics analysis, we identified a Gorilla transcript that is highly
424 homologous to human PLANE with 92% sequence similarity ([Supplementary Table 5](#)), suggesting
425 evolutionary conservation of PLANE between Hominidae. Nonetheless, no similarity was found
426 between PLANE and *Mus musculus*, a finding that precluded further testing the role of PLANE in
427 transgenic mouse models ([Supplementary Table 5](#)). Irrespectively, our results from functional and
428 correlative studies using human cell line models and human tissue samples suggest that PLANE
429 contributes to cancer development and progression driven by genomic amplification of the distal portion
430 of chromosome 3q and the cancer-promoting axis of E2F1 signalling ([Supplementary Fig. 9](#)). PLANE
431 may therefore represent a potential anti-cancer target for counteracting these oncogenic anomalies.

432 **METHODS**

433

434 **Cell culture and human tissues**

435

436 A549, MCF-7, HCT116, Eca109, and CCC-HIE-2 cells were maintained in DMEM (Biological
437 Industries, #01-052-1ACS; Beit Haemek, Israel) supplemented with 10% fetal bovine serum (FBS,
438 Biological Industries, #04-001-1A; Beit Haemek, Israel) and 1% penicillin-streptomycin (Biological
439 Industries, #03-031-1BCS, Beit Haemek, Israel). H1299, NCI-H1975 and NCI-H226 cells were
440 cultured in RPMI-1640 (Biological Industries, #01-100-1ACS; Beit Haemek, Israel) with 10% FBS and
441 1% penicillin-streptomycin. CCC-HSF-1 cells were cultured in DMEM/F12 (Biological Industries, #01-
442 172-1ACS; Beit Haemek, Israel) supplemented with 10% FBS and 1% penicillin-streptomycin. Cells
443 were cultured in a humidified incubator at 37 °C and 5% CO₂. All cell lines were verified to be free of
444 mycoplasma contamination every 3 months. Individual cell line authentication was confirmed using the
445 AmpFISTR Identifiler PCR Amplification Kit (ThermoFisher Scientific, #4427368) from Applied
446 Biosystems and GeneMarker V1.91 software (SoftGenetics LLC). Information on cell lines is provided
447 in [Supplementary Table 6](#). Formalin-fixed paraffin-embedded (FFPE) normal colon mucosa, colon
448 adenoma, COAD, LUAD and LUSC tissues were retrieved from archives of the Department of
449 Pathology at Shanxi Cancer Hospital (Taiyuan, China). Studies using human tissues were approved by
450 the Human Research Ethics Committees of the Shanxi Cancer Hospital in agreement with the guidelines
451 set forth by the Declaration of Helsinki.

452

453 **Antibodies and reagents**

454

455 Information on antibodies and reagents used in this study is provided in [Supplementary Tables 7 & 8](#),
456 respectively.

457

458 **SiRNAs and short hairpin RNA (shRNA) Oligos**

459

460 SiRNAs were obtained from GenePharma (Shanghai, China) and transfected using the lipofectamine
461 3000 Transfection Kit (ThermoFisher Scientific, #L3000-015). ShRNA oligos were purchased from
462 TSINGKE Biological Technology (Beijing, China).

463

464 **Plasmids**

465

466 The FH1-tUTG plasmid was a kind gift from A/Professor M. J. Herold (Walter and Eliza Hall Institute
467 of Medical Research, Australia). The pcDNA3.1(+), pGL4.73[hRluc/SV40] and pSin-3×Flag-E2F1
468 plasmids were kind gifts from Professor Mian Wu (Translational Research Institute, Henan Provincial
469 People's Hospital and People's Hospital of Zhengzhou University, Zhengzhou, China). The pEGFP-C1
470 plasmid was a kind gift from A/Professor Yongyan Wu (Department of Otolaryngology, Shanxi Key
471 Laboratory of Otorhinolaryngology Head and Neck Cancer, the first affiliated hospital, Shanxi Medical
472 University, Taiyuan, China). The pMDLg/pRRE plasmid (#12251), pMD2.g plasmid (#12259) and
473 pRSV-Rev plasmid (#12253) were purchased from Addgene. The pGL3-*PLANE*-promoter and the
474 pGL3-*PLANE*-promoter- Δ E2F1-BR were purchased from Sangon Biotech (Shanghai, China). Other
475 plasmids used in this study were generated by inserting the PCR products to the pcDNA3.1(+) or
476 pEGFP-C1 vectors. Primers used in the fusion PCR are shown in [Supplementary Table 9](#).

477

478 **Quantitative PCR (qPCR)**

479

480 Total RNA was extracted from cultured cells using the Gene JET RNA Purification Kit (ThermoFisher
481 Scientific, #K0731) according to the manufacturer's instructions. cDNA was synthesized from 1 μ g of
482 total RNA using the PrimScriptTM RT reagent Kit with gDNA Eraser (TaKaRa, #RR047A; Dalian,
483 China). Of the resultant cDNA, 12.5 ng was used in the 20 μ l qPCR mix, containing 10 μ l of TB Green
484 Premix Ex Taq II (Tli RNaseH Plus) (TaKaRa, #RP820A; Dalian, China) and 0.4 μ M of each primer.
485 Samples were amplified for 40 cycles using a StepOnePlusTM Real-Time PCR System (ThermoFisher
486 Scientific). $2^{-\Delta\Delta CT}$ method was used to calculate the relative gene expression levels normalized to the
487 GAPDH housekeeping control. Primer sequences are listed in [Supplementary Table 10](#).

488

489 **Chromatin Immunoprecipitation (ChIP)**

490

491 ChIP assays were performed using the ChIP Assay Kit (Beyotime, #P2078; Shanghai, China) according
492 to the manufacturer's instructions. Briefly, cells were cross-linked with a final concentration of 1%

493 formaldehyde in growth medium for 15 min at 37 °C and quenched by the addition of glycine solution
494 for 5 min at room temperature (RT). Then cells were harvested, lysed and sonicated. After being cleared
495 by centrifugation at 12,000 × g for 10 min at 4 °C, the cell lysate was subjected to a 1:10 dilution and
496 rotated with E2F1, H3K4me3 and H3K27me3 antibodies or corresponding mouse/rabbit normal
497 immunoglobulin (IgG) antibodies at 4 °C overnight. Then, 60 µl of protein A/G agarose beads was
498 added to the antibody-lysate mixture and rotated at 4 °C for an additional 1 hr. Beads were washed, and
499 DNA fragments were eluted, purified and subjected to PCR analysis using the specific primers. PCR
500 products were separated by gel electrophoresis on the 2% agarose gel. Information on antibodies and
501 primers used in this study are shown in [Supplementary Tables 7 & 11](#), respectively.

502 503 **Luciferase reporter assays**

504
505 A549 and H1299 cells were transfected with pGL3-*PLANE*-promoter reporters or pGL3-*PLANE*-
506 promoter-ΔE2F1-BR reporters together with pGL4.73[hRluc/SV40] reporters expressing the renilla
507 luciferase. After 48 hr, firefly and renilla luciferase activities were examined by a Dual-Luciferase®
508 Reporter Assay System (Promega, #E910) with a VARIOSKAN LUX microplate reader. The renilla
509 luciferase activity was used to normalize the firefly luciferase activity.

510 511 **Colony formation**

512
513 Cancer cells were seeded in six-well plates at 2,000 cells/well. After growing for further two weeks,
514 cells were fixed with methanol and staining with 0.5% crystal violet. The images were captured with a
515 Bio-Rad GelDoc™ XR + imaging system (Bio-Rad). The percentage and intensity of area covered by
516 crystal violet-stained cell colonies were quantified using ImageJ-plugin “ColonyArea”.

517 518 **Cell cycle analysis**

519
520 Cell cycle analysis was performed using the Cell Cycle and Apoptosis Analysis Kit (Meilunbio,
521 #MA0334; Dalian, China) according to the manufacturer’s instructions followed by flow cytometry.
522 Briefly, A549 and H1299 cells transfected with *PLANE* siRNAs for 48 hr in 24-well plates were
523 harvested and fixed in 75% ethanol at 4 °C overnight. After being centrifuged, cells were incubated in

524 the staining solution at 37 °C in the dark for 30 min. Then cells were subjected to analysis using a flow
525 cytometer (FACSAria, BD Biosciences).

526

527 **Anchorage-independent cell growth**

528

529 Cells carrying an inducible PLANE knockdown in response to Dox were seeded in the Ultra-Low
530 attachment 6-well plate (Corning, #3471) at 2,000 cells/well. Cells with or without treatment with
531 doxycycline (Dox) and cessation of Dox treatment were incubated at 37 °C in a humidified incubator
532 until colonies were formed. Colonies were counted under a light microscope²⁹.

533

534 **In situ hybridization (ISH)**

535

536 ISH assays were performed using the RNAscope[®] 2.5 HD Detection Reagent-BROWN (Advanced Cell
537 Diagnostics, #322310) according to the manufacturer's instructions^{37, 58}. Briefly, FFPE LUSC and
538 LUAD as well as COAD tissue microarrays (#HLug-Squ150Sur-02, #HLugA180Su03,
539 #HColA180Su12) purchased from the Shanghai Outdo Biotech Co., Ltd (China) were deparaffinized in
540 xylene for 5 min at RT twice, followed by dehybridization in 100% alcohol. After being air-dried, the
541 tissue sections were incubated with hydrogen peroxide for 10 min at RT and washed in the distilled
542 water for five times. Then the sections were heated in target retrieval reagent to 100 °C for 20 min,
543 followed by being treated with proteinase K and incubated in hybridization buffer containing probes
544 (Advanced Cell Diagnostics, #570031) at 40 °C for 3 hr. After being washed, the sections were
545 incubated with 3,3'-diaminobenzidine (DAB), and counterstaining was carried out using hematoxylin.

546

547 The percentage of positive cells was ranged from 0 to 100%. The intensity of staining (intensity score)
548 was judged on an arbitrary scale of 0 to 4: no staining (0), weakly positive staining (1), moderately
549 positive staining (2), strongly positive staining (3) and very strong positive staining (4). A reactive score
550 (RS) was derived by multiplying the percentage of positive cells with staining intensity divided by 10.

551

552 **Immunofluorescence (IF)**

553

554 Cells grown on coverslips were fixed in 4% formaldehyde for 10 min at RT. After being washed using
555 PBS, cells were then permeabilized in blocking buffer for 60 min at RT. Antibodies diluted 1:500 in
556 blocking buffer were incubated with cells overnight at 4 °C. Cells were washed in PBS and incubated
557 with secondary antibodies diluted 1:200 in blocking buffer for 60 min at RT in the dark. After being
558 washed, cells were mounted in the ProLong™ Glass Antifade Mountant with NucBlue reagent
559 (ThermoFisher Scientific, P36981). Images were digitally recorded using a Leica SP8 confocal
560 microscope. Information of antibodies used in this study was shown in [Supplementary Table 7](#).

561 562 **Subcellular fractionation**

563
564 Cells were harvested by trypsinization and lysed in hypotonic buffer A (10 mM Hepes pH 7.9, 10 mM
565 KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.15% Triton X-100, cOmplete™, EDTA-free
566 Protease Inhibitor Cocktail) on ice for 15 min. The supernatants after centrifugation at 12,000 × g for 3
567 min were collected as the cytoplasmic fractions and the pellets were subjected to the nuclear
568 fractionation. The pellets were rinsed with cold PBS once and lysed in an equal volume of buffer B (20
569 mM Hepes pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.5% Triton X-100,
570 cOmplete™, EDTA-free Protease Inhibitor Cocktail) on ice for 15 min. Cytoplasmic and nuclear
571 fractions were centrifuged at 16,000 × g for 20 min to remove the insoluble debris. The supernatants
572 were collected for RNA isolation and immunoblotting analysis.

573 574 ***In vitro* transcription**

575
576 The DNA templates used for *in vitro* synthesis of PLANE, antisense PLANE and NCOR2 pre-mRNA
577 were generated by PCR amplification from cDNAs using PrimerSTAR Max DNA Polymerase
578 (TAKARA, #R045A; Dalian, China). Forward primers containing the T7 RNA polymerase promoter
579 sequence and reverse primers without the promoter sequence were used for synthesizing PLANE,
580 antisense PLANE, and NCOR2 pre-mRNA. After PCR amplification, the products were purified using
581 a MiniBEST Agarose Gel DNA Extraction Kit (Takara, #9762; Dalian, China), and subjected to *in vitro*
582 transcription using a TranscriptAid T7 High Yield Transcription Kit (ThermoFisher Scientific, #K0441)
583 according to the manufacturer's instructions. The *in vitro*-transcribed RNAs could be further labelled

584 with biotin using a PierceTM RNA 3' End Desthiobiotinylation Kit (ThermoFisher Scientific, #20163).

585 Primer sequences are shown in [Supplementary Table 11](#).

586

587 **Domain-specific chromatin isolation by RNA purification (dChIRP)**

588

589 dChIRP assays were performed as previous described⁵⁹. Briefly, A549 and H1299 cells were harvested

590 and cross-linked in 1% glutaraldehyde for 10 min at RT with rotation. The cross-linked cells were lysed

591 in lysis buffer (50 mM Tris-Cl [pH 7.0], 10 mM EDTA, 1% SDS, PMSF, Suprase-in), followed by

592 sonication. 4 µg antisense / sense biotin-labelled probes or 10 µg *in vitro*-transcribed biotin-labelled

593 PLANE / antisense PLANE were rotated with cell lysates at 37 °C for 4 hr, followed by adding 100 µl

594 C-1 magnetic beads (Invitrogen, #65002) to each sample and incubating at 37 °C for 30 min with rotation.

595 Beads were then washed in wash buffer for five times, followed by RNA isolation. Probe sequences are

596 shown in [Supplementary Table 11](#).

597

598 **Biotin RNA pull-down (RPD)**

599

600 A549 and H1299 cells were harvested and washed in PBS for three times. Cell pellets were then lysed

601 in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 2.5 mM MgCl₂, 1 mM EDTA, 10% Glycerol,

602 0.5% Nonidet P-40/Igepal CA-630, 1 mM DTT, cOmpleteTM EDTA-free Protease Inhibitor Cocktail

603 and RNase inhibitors) and sonicated. 4 µg antisense / sense biotin-labelled probes were incubated with

604 lysates at 4 °C overnight before rotating with streptavidin beads (ThermoFisher Scientific, #20349) for

605 additional 2 hr. Beads were then washed in lysis buffer for four times, followed by RNA isolation and

606 immunoblotting analysis. Information of antibodies and probes is shown in [Supplementary Tables 7 &](#)

607 [11](#), respectively.

608

609 **Mass spectrometry (MS) analysis**

610

611 Proteins co-pulled down with RNA using antisense / sense biotin-labelled probes were separated by 10%

612 acrylamide gels and visualized by Coomassie brilliant blue staining. The specific protein band shown in

613 the group using antisense probes along with the corresponding region in the group using sense probes

614 were resected and digested, followed by the liquid chromatography–mass spectrometry (LS-MS)

615 analysis using a mass spectrometer (ThermoFisher Scientific, EASY-nLC1000 & LTQ Orbitrap Velos
616 Pro). Proteins identified from the mass spectrometry analysis are listed in [Supplementary Table 4](#).

617
618 **RNA immunoprecipitation (RIP)**

619
620 RIP assays were performed using a Magna RIPTM Kit (Millipore, #17-700; Darmstadt, Germany)
621 according to the instruction provided by the manufacturer. Briefly, cell lysates prepared in hypotonic
622 buffer supplemented with RNase inhibitor and protease inhibitor were incubated with magnetic beads
623 pre-incubated with hnRNPM antibodies at 4 °C overnight. After being washed with RIP wash buffer,
624 the bead-bound immunocomplexes were subjected to immunoblotting analysis and RNA isolation.
625 Information on antibody and primers used in this study is shown in [Supplementary Tables 7 & 11](#).

626
627 **Immunoprecipitation (IP)**

628
629 Cells were collected with trypsinization and lysed with lysis buffer (20 mM Tris-HCl pH 8.6, 100 mM
630 NaCl, 20 mM KCl, 1.5 mM MgCl₂, 0.5% NP-40, cOmpleteTM EDTA-free Protease Inhibitor Cocktail)
631 on ice for 1 hr and centrifuged at 16,000 × g for 30 min. After quantification using a BCA protein assay
632 kit (ThermoFisher, #23225), 3 mg of total protein were rotated with antibodies at 4 °C overnight.
633 Protein-antibody complexes were then captured with the PierceTM Protein A/G Agarose (ThermoFisher
634 Scientific, #20421) at 4°C for 2 hrs with rotation and beads were then rinsed with wash buffer (25 mM
635 Tris, 150 mM NaCl, pH 7.2), boiled and subjected to immunoblotting analysis. Antibodies used in this
636 study are shown in [Supplementary Table 7](#).

637
638 **Absolute quantification of PLANE**

639
640 Absolute RNA quantification was performed using the standard curve method by qPCR. cDNA was
641 synthesized using 1 µg of the total RNA extracted from a fixed cell number. Ten-fold serial dilutions of
642 the pcDNA3.1-PLANE plasmid (10² to 10⁷ molecules per ml) were used as a reference molecule for the
643 standard curve calculation. Assays were reconstituted to a final volume of 20 µl using 5 µl cDNA from
644 cells or 5 µl serial diluted pcDNA3.1-PLANE plasmid and cycled using a StepOnePlusTM Real-Time

645 PCR System. Data calculated as copies per 5 μ l cDNA were converted to copies per cell based on the
646 known input cell equivalents. Primer sequences used are listed in [Supplementary Table 10](#).

647

648 **Inducible shRNA knockdown**

649

650 The FH1-tUTG inducible knockdown vector was digested using BsmBII (NEW ENGLAND BioLabs,
651 #R0580S) and XhoI (NEW ENGLAND BioLabs, #R0146S) enzymes, and the annealed shRNA oligos
652 were inserted into the digested vector using the T4 DNA ligase (ThermoFisher Scientific, #EL0014).

653 The lentiviral particles were packaged via co-transfection of FH1-tUTG vector inserted with shRNA
654 oligos (44 μ g), pMDLg/pRRE plasmid (22 μ g), pMD2.g plasmid (13.2 μ g) and pRSV-Rev plasmid (11
655 μ g) plasmids into HEK293T cells⁶⁰. A549 or H1299 cells were transduced with the lentiviral particles
656 in 6 cm cell culture dishes to establish inducible knockdown cell sublines. The knockdown of PLANE
657 was induced in response to doxycycline treatment. ShRNA sequences are shown in [Supplementary](#)
658 [Table 12](#).

659

660 **Xenograft mouse model**

661

662 A549 cells expressing the inducible PLANE shRNAs were subcutaneously injected into the dorsal
663 flanks of 4-week-old female nude mice (6 mice per group, Shanghai SLAC Laboratory Animal Co. Ltd.,
664 China). Tumor growth was measured every 3 days using a calliper. Mice were sacrificed after 33 days
665 of cancer cell transplantation. Tumors were excised and measured. Studies on animals were conducted
666 in accordance with relevant guidelines and regulations and were approved by the Animal Research
667 Ethics Committee of the first affiliated hospital, Shanxi Medical University and Shanxi Cancer Hospital
668 and Institute (China). All mice were housed in a temperature-controlled room (21-23 °C) with 40–60%
669 humidity and a light/dark cycle of 12 h/12 h.

670

671 **Statistical Analysis**

672

673 Statistical analysis was carried out using the GraphPad Prism 8 to assess differences between
674 experimental groups. Statistical differences were analyzed by two-tailed Student's *t*-test or one-way

675 ANOVA test followed by Tukey's multiple comparisons. *P* values lower than 0.05 were considered to
676 be statistically significant.

677

678 **DATA AVAILABILITY**

679

680 The RNA sequencing data have been deposited in the NCBI Gene Expression Omnibus database under
681 the accession code GSE162215. The mass spectrometry proteomics data have been deposited to the
682 ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the iProX partner
683 repository with the dataset identifier PXD022747. The long noncoding RNA expression data and E2F1
684 mRNA expression data referenced during the study are available in a public repository from the Cancer
685 RNA-seq Nexus dataset (<http://syslab4.nchu.edu.tw/>). The cancer patient survival data referenced
686 during the study are available in a public repository from the GEPIA website ([http://gepia.cancer-](http://gepia.cancer-pku.cn/)
687 [pku.cn/](http://gepia.cancer-pku.cn/)) under the accession codes TCGA-LUSC, TCGA-COAD, TCGA-KIRC and TCGA-UCEC. The
688 gene amplification frequency data referenced during the study are available in a public repository from
689 the cBioPortal website (<https://www.cbioportal.org/>) under the accession code TCGA PanCancer Atlas
690 Studies.

691 **REFERENCES**

- 692
693 1. Goodall GJ, Wickramasinghe VO. RNA in cancer. *Nat Rev Cancer*, (2020).
694
695 2. Wang ET, *et al.* Alternative isoform regulation in human tissue transcriptomes. *Nature* **456**,
696 470-476 (2008).
697
698 3. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing
699 complexity in the human transcriptome by high-throughput sequencing. *Nat Genet* **40**, 1413-
700 1415 (2008).
701
702 4. Matera AG, Wang Z. A day in the life of the spliceosome. *Nat Rev Mol Cell Biol* **15**, 108-121
703 (2014).
704
705 5. Mitra M, Lee HN, Collier HA. Splicing Busts a Move: Isoform Switching Regulates Migration:
706 (Trends in Cell Biology 30, 74-85, 2020). *Trends Cell Biol* **30**, 255 (2020).
707
708 6. Frankiw L, Baltimore D, Li G. Alternative mRNA splicing in cancer immunotherapy. *Nat Rev*
709 *Immunol* **19**, 675-687 (2019).
710
711 7. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone
712 receptors. *Nature* **377**, 454-457 (1995).
713
714 8. Sande S, Privalsky ML. Identification of TRACs (T3 receptor-associating cofactors), a family
715 of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. *Mol*
716 *Endocrinol* **10**, 813-825 (1996).
717
718 9. Mottis A, Mouchiroud L, Auwerx J. Emerging roles of the corepressors NCoR1 and SMRT in
719 homeostasis. *Genes Dev* **27**, 819-835 (2013).
720
721 10. Lee SK, Kim JH, Lee YC, Cheong J, Lee JW. Silencing mediator of retinoic acid and thyroid
722 hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1,
723 nuclear factor-kappaB, and serum response factor. *J Biol Chem* **275**, 12470-12474 (2000).
724
725 11. Jonas BA, Varlakhanova N, Hayakawa F, Goodson M, Privalsky ML. Response of SMRT
726 (silencing mediator of retinoic acid and thyroid hormone receptor) and N-CoR (nuclear receptor
727 corepressor) corepressors to mitogen-activated protein kinase kinase cascades is
728 determined by alternative mRNA splicing. *Mol Endocrinol* **21**, 1924-1939 (2007).
729
730 12. Goodson ML, Jonas BA, Privalsky ML. Alternative mRNA splicing of SMRT creates functional
731 diversity by generating corepressor isoforms with different affinities for different nuclear
732 receptors. *J Biol Chem* **280**, 7493-7503 (2005).
733
734 13. Faist F, Short S, Kneale GG, Sharpe CR. Alternative splicing determines the interaction of
735 SMRT isoforms with nuclear receptor-DNA complexes. *Biosci Rep* **29**, 143-149 (2009).
736
737 14. Ghoshal P, *et al.* Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression
738 in multiple myeloma. *Cancer Res* **69**, 4380-4387 (2009).
739
740 15. Song L, *et al.* Alteration of SMRT tumor suppressor function in transformed non-Hodgkin
741 lymphomas. *Cancer Res* **65**, 4554-4561 (2005).
742
743 16. Compton LA, Hiebert SW. Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT
744 interaction in B cell lymphoma. *Cancer Cell* **17**, 315-316 (2010).

- 745
746 17. Alam H, *et al.* HP1gamma Promotes Lung Adenocarcinoma by Downregulating the
747 Transcription-Repressive Regulators NCOR2 and ZBTB7A. *Cancer Res* **78**, 3834-3848 (2018).
748
749 18. Smith CL, *et al.* Elevated nuclear expression of the SMRT corepressor in breast cancer is
750 associated with earlier tumor recurrence. *Breast Cancer Res Treat* **136**, 253-265 (2012).
751
752 19. Chen S, Thorne RF, Zhang XD, Wu M, Liu L. Non-coding RNAs, guardians of the p53 galaxy.
753 *Semin Cancer Biol*, (2020).
754
755 20. Zhang L, Xu X, Su X. Noncoding RNAs in cancer immunity: functions, regulatory mechanisms,
756 and clinical application. *Mol Cancer* **19**, 48 (2020).
757
758 21. Liu X, *et al.* Non-coding RNAs, metabolic stress and adaptive mechanisms in cancer. *Cancer*
759 *Lett* **491**, 60-69 (2020).
760
761 22. Schmitt AM, Chang HY. Long Noncoding RNAs in Cancer Pathways. *Cancer Cell* **29**, 452-
762 463 (2016).
763
764 23. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. *Mol Cell* **43**, 904-914
765 (2011).
766
767 24. Romero-Barrios N, Legascue MF, Benhamed M, Ariel F, Crespi M. Splicing regulation by long
768 noncoding RNAs. *Nucleic Acids Res* **46**, 2169-2184 (2018).
769
770 25. Passacantilli I, Frisone P, De Paola E, Fidaleo M, Paronetto MP. hnRNPM guides an alternative
771 splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma
772 cells. *Nucleic Acids Res* **45**, 12270-12284 (2017).
773
774 26. Tripathi V, *et al.* The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing
775 by modulating SR splicing factor phosphorylation. *Mol Cell* **39**, 925-938 (2010).
776
777 27. Kong J, *et al.* Long non-coding RNA LINC01133 inhibits epithelial-mesenchymal transition
778 and metastasis in colorectal cancer by interacting with SRSF6. *Cancer Lett* **380**, 476-484 (2016).
779
780 28. Villamizar O, Chambers CB, Riberdy JM, Persons DA, Wilber A. Long noncoding RNA Saf
781 and splicing factor 45 increase soluble Fas and resistance to apoptosis. *Oncotarget* **7**, 13810-
782 13826 (2016).
783
784 29. Feng YC, *et al.* c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer
785 pathogenesis. *Nat Commun* **11**, 4980 (2020).
786
787 30. Qian J, Massion PP. Role of chromosome 3q amplification in lung cancer. *J Thorac Oncol* **3**,
788 212-215 (2008).
789
790 31. Singh B, *et al.* Molecular cytogenetic characterization of head and neck squamous cell
791 carcinoma and refinement of 3q amplification. *Cancer Res* **61**, 4506-4513 (2001).
792
793 32. Umayahara K, *et al.* Comparative genomic hybridization detects genetic alterations during early
794 stages of cervical cancer progression. *Genes Chromosomes Cancer* **33**, 98-102 (2002).
795
796 33. Sattler HP, *et al.* Novel amplification unit at chromosome 3q25-q27 in human prostate cancer.
797 *Prostate* **45**, 207-215 (2000).
798

- 799 34. Lambros MB, *et al.* Analysis of ovarian cancer cell lines using array-based comparative
800 genomic hybridization. *J Pathol* **205**, 29-40 (2005).
801
- 802 35. Fornes O, *et al.* JASPAR 2020: update of the open-access database of transcription factor
803 binding profiles. *Nucleic Acids Res* **48**, D87-D92 (2020).
804
- 805 36. O'Leary NA, *et al.* Reference sequence (RefSeq) database at NCBI: current status, taxonomic
806 expansion, and functional annotation. *Nucleic Acids Res* **44**, D733-745 (2016).
807
- 808 37. Yari H, *et al.* LncRNA REG1CP promotes tumorigenesis through an enhancer complex to
809 recruit FANCD1 helicase for REG3A transcription. *Nat Commun* **10**, 5334 (2019).
810
- 811 38. Vaquero-Garcia J, *et al.* A new view of transcriptome complexity and regulation through the
812 lens of local splicing variations. *Elife* **5**, e11752 (2016).
813
- 814 39. Mann M, Wright PR, Backofen R. IntaRNA 2.0: enhanced and customizable prediction of
815 RNA-RNA interactions. *Nucleic Acids Res* **45**, W435-W439 (2017).
816
- 817 40. Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and
818 disease. *Hum Genet* **135**, 851-867 (2016).
819
- 820 41. West KO, Scott HM, Torres-Odio S, West AP, Patrick KL, Watson RO. The Splicing Factor
821 hnRNP M Is a Critical Regulator of Innate Immune Gene Expression in Macrophages. *Cell Rep*
822 **29**, 1594-1609 e1595 (2019).
823
- 824 42. Spector DL, Lamond AI. Nuclear speckles. *Cold Spring Harb Perspect Biol* **3**, (2011).
825
- 826 43. Preusser C, Rossbach O, Hung LH, Li D, Bindereif A. Genome-wide RNA-binding analysis of
827 the trypanosome U1 snRNP proteins U1C and U1-70K reveals cis/trans-spliceosomal network.
828 *Nucleic Acids Res* **42**, 6603-6615 (2014).
829
- 830 44. Massion PP, *et al.* Genomic copy number analysis of non-small cell lung cancer using array
831 comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.
832 *Cancer Res* **62**, 3636-3640 (2002).
833
- 834 45. Comtesse N, *et al.* Frequent overexpression of the genes FXR1, CLAPM1 and EIF4G located
835 on amplicon 3q26-27 in squamous cell carcinoma of the lung. *Int J Cancer* **120**, 2538-2544
836 (2007).
837
- 838 46. Meng P, Ghosh R. Transcription addiction: can we garner the Yin and Yang functions of E2F1
839 for cancer therapy? *Cell Death Dis* **5**, e1360 (2014).
840
- 841 47. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG.
842 Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53.
843 *Proc Natl Acad Sci U S A* **95**, 8858-8863 (1998).
844
- 845 48. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue
846 atrophy in mice lacking E2F-1. *Cell* **85**, 537-548 (1996).
847
- 848 49. Gong C, *et al.* BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-
849 Resistant Breast Cancer. *Clin Cancer Res* **24**, 3681-3691 (2018).
850
- 851 50. Goodson ML, Mengeling BJ, Jonas BA, Privalsky ML. Alternative mRNA splicing of
852 corepressors generates variants that play opposing roles in adipocyte differentiation. *J Biol*
853 *Chem* **286**, 44988-44999 (2011).

- 854
855 51. Beltran M, *et al.* A natural antisense transcript regulates *Zeb2/Sip1* gene expression during
856 Snail1-induced epithelial-mesenchymal transition. *Genes Dev* **22**, 756-769 (2008).
857
858 52. Hovhannisyanyan RH, Carstens RP. Heterogeneous ribonucleoprotein m is a splicing regulatory
859 protein that can enhance or silence splicing of alternatively spliced exons. *J Biol Chem* **282**,
860 36265-36274 (2007).
861
862 53. Xu Y, *et al.* Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via
863 regulating alternative splicing. *Genes Dev* **28**, 1191-1203 (2014).
864
865 54. Zhang FL, *et al.* Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated
866 CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
867 *Cancer Res* **78**, 5780-5792 (2018).
868
869 55. Fu XD, Ares M, Jr. Context-dependent control of alternative splicing by RNA-binding proteins.
870 *Nat Rev Genet* **15**, 689-701 (2014).
871
872 56. Fredericks AM, Cygan KJ, Brown BA, Fairbrother WG. RNA-Binding Proteins: Splicing
873 Factors and Disease. *Biomolecules* **5**, 893-909 (2015).
874
875 57. Beck M, *et al.* The quantitative proteome of a human cell line. *Mol Syst Biol* **7**, 549 (2011).
876
877 58. Hu WL, *et al.* GUARDIN is a p53-responsive long non-coding RNA that is essential for
878 genomic stability. *Nat Cell Biol* **20**, 492-502 (2018).
879
880 59. Quinn JJ, *et al.* Revealing long noncoding RNA architecture and functions using domain-
881 specific chromatin isolation by RNA purification. *Nat Biotechnol* **32**, 933-940 (2014).
882
883 60. Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Inducible and reversible gene silencing
884 by stable integration of an shRNA-encoding lentivirus in transgenic rats. *Proc Natl Acad Sci U*
885 *SA* **105**, 18507-18512 (2008).
886
887

888 **ACKNOWLEDGEMENTS**

889

890 This work was supported by the National Health and Medical Research Council (NHMRC;
891 APP1147271, APP1162753, APP1177087) and Cancer Council NSW Project Grant (RG20-10),
892 Australia. The authors thank A/Professor M. J. Herold (Walter and Eliza Hall Institute of Medical
893 Research, Australia) for the plasmid FH1tUTG, Professor Xiao Ying Liu (Translational Research
894 Institute, Henan Provincial People's Hospital, China) and Professor Xiaojun Zhang (Respiration
895 Department, Henan Provincial People's Hospital, Zhengzhou, China) for providing the Eca109 and
896 NCI-H1975 as well as NCI-H226 cell lines, respectively. The authors thank the Shanghai luming
897 biological technology co., LTD (Shanghai, China) for providing proteomics services.

898

899 **AUTHOR CONTRIBUTIONS**

900

901 X.D.Z., F.-M.S., L.J., and T. Liu designed the experiments. X.D.Z., F.-M.S., and L.J. supervised the

902 work. L.T., Y.C.F., P.L.W., S.X.W., T.F.Q., S.N.Z., T.La, Y.Y.Z., X.H.Z., D.Z., and J.Y.W. performed

903 experiments using human cell lines and tissues and related data collections; S.T.G. conducted

904 experiments in xenograft models; T.Liu, J.M.L., Y.C.F., L.J., T.La, R.F.T., and J.Y.W. carried out

905 analysis of publicly available data and bioinformatics analysis. X.D.Z., R.F.T., F.-M.S., T.Liu, and L.J.

906 wrote the manuscript. All authors commented on the manuscript.

907

908 **DECLARATION OF COMPETING INTERESTS**

909

910 The authors declare no competing interests.

Figure 1




Figure 1. Genomic amplification and transcriptional activation by E2F1 drive PLANE expression that is upregulated in diverse cancer types

a Representative microscopic photographs of *in situ* hybridization (ISH) analysis of PLANE expression in formalin-fixed paraffin-embedded (FFPE) LUSC, LUAD and COAD tissues (n=75, 87 and 79 biologically independent samples, respectively) compared with corresponding paired adjacent normal tissues. Quantitation of PLANE expression in cancer relative to paired normal tissues is also shown. Scale bar, 5 μ m. RS: reactive score. Two-tailed Student's *t*-test.

b Kaplan-Meier analysis of the probability of overall survival of LUSC (n = 495) and COAD (n = 268) patients derived from the TCGA datasets using the quartile (LUSC) or median (COAD) of PLANE levels as the cutoff.

c qPCR analysis of genomic DNA from LUSC (n=22) and LUAD (n=24) tissues and corresponding paired adjacent normal tissues. A ≥ 1.5 -fold increase in the copy number in the cancer tissue relative to the corresponding normal tissue is considered genomic amplification.

d qPCR analysis of genomic DNA from the indicated cancer cell lines and the normal human intestinal epithelial cell line CCC-HIE-2. The copy number of *PLANE* in the CCC-HIE-2 cell line was arbitrarily designated as 1. A ≥ 1.5 -fold increase in the copy number in cancer cell lines compared with the CCC-HIE-2 line is considered genomic amplification. Data are mean \pm s.d.; n = 3 independent experiments.

e Absolute quantitation of PLANE in A549 and H1299 cancer cells and normal human CCC-HSF-1 fibroblasts using qPCR. Data are mean \pm s.d.; n = 3 independent experiments, one-way ANOVA followed by Tukey's multiple comparisons test.

f Chromatin immunoprecipitation (ChIP) analysis of the association between endogenous E2F1 and the region enriched of E2F1 binding motifs at the promoter of *PLANE* in A549 and H1299 cells. Data are representatives of 3 independent experiments.

g The transcriptional activity of a *PLANE* reporter construct was reduced by deletion of the E2F1-binding region (E2F1-BR) at the promoter of *PLANE* in A549 and H1299 cells. Data are mean \pm s.d.; n = 3 independent experiments, two-tailed Student's *t*-test. FL: Firefly luciferase activity; RL: Renilla luciferase activity.

h E2F1 silencing downregulated PLANE expression in H1299 and HCT116 cells. Data are representatives or mean \pm s.d.; n = 3 independent experiments, one-way ANOVA followed by Tukey's multiple comparisons test.

Figure 2




Figure 2. PLANE promotes cancer cell proliferation and tumorigenicity

a-c siRNA knockdown of PLANE (a) inhibited 5-bromo-2'-deoxyuridine (BrdU) incorporation (b) and clonogenicity (c) in multiple cancer cell lines. Relative clonogenicity was quantitated using ImageJ-plugin 'ColonyArea'. Data are mean \pm s.d. or representatives; $n = 3$ independent experiments, two-tailed Student's *t*-test. Scale bar, 1 cm.

d Induced knockdown of PLANE by the addition of doxycycline (Dox, 500 nM) in A549.shPLANE and H1299.shPLANE cells. Data are mean \pm s.d.; $n = 3$ independent experiments, two-tailed Student's *t*-test. **e** Doxycycline (Dox, 500nM)-induced knockdown of PLANE inhibited A549.shPLANE and H1299.shPLANE cell proliferation as shown by decelerated cell number increases. Data are mean \pm s.d.; $n = 3$ independent experiments, two-tailed Student's *t*-test.

f Induced knockdown of PLANE inhibited A549.shPLANE and H1299.shPLANE cell clonogenicity, which was partially reversed by cessation of Dox treatment. Relative clonogenicity of cells was quantitated using ImageJ-plugin 'ColonyArea'. Data are representatives or mean \pm s.d.; $n = 3$ independent experiments, one-way ANOVA followed by Tukey's multiple comparisons test. Scale bar, 1 cm.

g. Representative microscopic photographs of anchorage-independent growth of A549.shPLANE and H1299.shPLANE cells with or without treatment with Dox and cessation of Dox treatment. Quantification of anchorage-independent growth of the cells is also shown. Scale bar, 0.5 mm. Data are representatives or mean \pm s.d.; $n = 3$ independent experiments, one-way ANOVA followed by Tukey's multiple comparisons test.

h & i Representative photographs (h) and growth curves (i) of A549.shPLANE xenografts in nu/nu mice with or without treatment with Dox (2 mg/ml supplemented with 10 mg/ml sucrose in drinking water) and cessation of Dox treatment. Data are representatives or mean \pm s.d.; $n = 6$ mice per group, one-way ANOVA followed by Tukey's multiple comparison test. DOX: 2 mg/ml supplemented with 10 mg/ml sucrose in drinking water.

Figure 3




Figure 3. PLANE represses NCOR2-202-generating AS event

a Volcano plot of transcript expression derived from RNA-seq data showing that the NCOR2 AS variant NCOR2-202 was the most upregulated transcript and the only NCOR2 AS variant that was increased in A549 cells caused by siRNA knockdown of PLANE. Red dots represent NCOR2 AS variants. n = 2 experimental repeats.

b qPCR analysis using primers spanning across a common region present in NCOR2-001, NCOR2-202 and NCOR2-005 and Western blotting analysis using an anti-NCOR2 antibody against residues near its N-terminus that is conserved in NCOR2 protein isoform NCOR2-3, -1 and -2 encoded individually by NCOR2-001, NCOR2-202 and NCOR2-005 showing upregulation of NCOR2 at the mRNA and protein levels, respectively, by induced knockdown of PLANE in A549.shPLANE and H1299.shPLANE cells.

Data are representatives or mean \pm s.d.; n = 3 independent experiments, two-tailed Student's *t*-test.

c Overexpression of PLANE caused downregulation of NCOR2 at the protein level in A549 and H1299 cells. Data are representatives or mean \pm s.d.; n = 3 independent experiments, two-tailed Student's *t*-test.

d Inducible knockdown of PLANE promoted the NCOR2-202-generating AS event but did not affect the AS event giving rise to NCOR2-001 and NCOR2-005 as shown in RT-PCR analysis. Data are representatives of 3 independent experiments.

e Relative levels of NCOR2-202/-001/-005 in cells with or without induced knockdown of PLANE as shown in **d**. Data are representatives of 3 independent experiments.

f Overexpression of PLANE reduced the NCOR2-202-generating AS event but did not affect the AS event giving rise to NCOR2-005 as shown in RT-PCR analysis.

g Relative levels of NCOR2-202/-001/-005 in cells with or without overexpression of PLANE as shown in **f**. Data are representatives of 3 independent experiments.

h & i Co-knockdown of NCOR2 using siRNA partially reversed siRNA-knockdown of PLANE-induced inhibition of A549 cell proliferation as shown by decelerated cell number increases (**h**) and clonogenicity (**i**). Relative clonogenicity of cells was quantitated using ImageJ-plugin 'ColonyArea'. Data are representatives or mean \pm s.d.; n = 3 independent experiments, one-way ANOVA followed by Tukey's multiple comparison test.

j MAJIQ analysis of RNA-seq data (two experimental repeats) showing the categorization of alternative splicing events caused by PLANE knockdown in A549 cells. LSVs, local splicing variations; Alt 5' SS, Alternative 5' splicing site; Alt 3' SS, Alternative 3' splicing site. MAJIQ, modelling alternative junction inclusion quantification.

k RT-PCR analysis of the indicated AS events using primers flanking PLANE-regulated alternative exons. Relative levels of relevant AS variants quantitated using densitometry are also shown. Data are representatives of 3 independent experiments. DNHD1, Dynein Heavy Chain Domain 1; ADH6, Alcohol Dehydrogenase 6; SLC25A14, Solute Carrier Family 25 Member 14; RRBP1, Ribosome Binding Protein 1; PTPN4, Protein Tyrosine Phosphatase Non-Receptor Type 4.

Figure 4




Figure 4. PLANE forms an RNA-RNA duplex with the NCOR2 pre-mRNA

a Representative microphotographs of *in situ* hybridization (ISH) analysis of PLANE expression in A549 cells grown on coverslips. Analysis of DapB and PPIB RNA expression was included as a negative and a positive control, respectively. Scale bar, 10 μ m. Data are representatives of 3 independent experiments.

b qPCR analysis of PLANE expression in the nuclear and cytoplasmic fractions of A549 and H1299 cells. Analysis of U6 and β -actin RNA expression was included as controls. Data are mean \pm s.d.; n = 3 independent experiments, two-tailed Student's *t*-test. Cyt: cytoplasm; Nuc: nucleus.

c *In vitro*-synthesized biotin-labelled PLANE bound to the PLANE binding region (PLANE-BR) of *in vitro*-transcribed intron 45 of NCOR2 pre-mRNA as shown in domain-specific chromatin isolation by RNA purification (dChIRP) assays. This binding was abolished when the PLANE-BR at NCOR2 pre-mRNA or the duplex-forming oligonucleotides (DFOs) within PLANE were deleted (intron 45- Δ PLANE-BR and PLANE- Δ DFOs, respectively). Data are representatives of 3 independent experiments.

d *In vitro*-transcribed biotin-labelled PLANE did not precipitate *in vitro*-transcribed intron 47 of the NCOR2 pre-mRNA that does not contain the PLANE-BR as shown in dChIRP assays. Data are representatives of 3 independent experiments. AS, antisense.

e *In vitro*-synthesized biotin-labelled PLANE precipitated the endogenous NCOR2 pre-mRNA in A549 and H1299 cell nuclear extracts as shown in dChIRP assays. Data are representatives of 3 independent experiments.

f Endogenous PLANE coprecipitated a fragment of the endogenous NCOR2 pre-mRNA containing the intact PLANE-BR but not a non-PLANE-BR-containing fragment (intron 47 of NCOR2 pre-mRNA) as shown in dChIRP assays. Data are representatives of 3 independent experiments. S, sense; AS, antisense.

g PLANE co-precipitated a fragment of intron 45 of the NCOR2 pre-mRNA containing the PLANE-BR in A549 cells treated with proteinase K as shown in dChIRP assays. Data are representatives of 3 independent experiments.

h & i Expression of a PLANE mutant with the DFOs deleted (PLANE- Δ DFOs) did not affect the NCOR2-202-generating splicing event (h) and 5-bromo-2'-deoxyuridine (BrdU) incorporation (i). Data are representatives or mean \pm s.d.; n = 3 independent experiments, two-tailed Student's *t*-test.

j Expression of a shRNA-resistant PLANE mutant (PLANE-R) diminished the enhancement of the NCOR2-202-generating AS event caused by induced knockdown of PLANE in A549.shPLANE.1 cells. Data are representatives of 3 independent experiments.

k Relative levels of NCOR2-202/-001-/005 as shown in **j** quantitated using densitometry. Data are representatives of 3 independent experiments.

Figure 5




Figure 5. PLANE interacts with hnRNPM

a RNA pulldown followed by mass spectrometry analysis identified that hnRNPM is the most abundant protein co-pulled down with PLANE antisense probes in A549 and H1299 cells. S: sense; AS: antisense. n = 1 experiment.

b hnRNPM was co-pulled down with PLNAE in A549 and H1299 cells as shown in RNA pulldown assays. hnRNPK was included as a negative control. S, sense; AS, antisense. Data are representatives of 3 independent experiments.

c PLANE was coprecipitated with hnRNPM in A549 and H1299 cells as shown in RNA immunoprecipitation (RIP) assays. The lncRNA lncCyt b was included as a negative control. Data are representatives of 3 independent experiments.

d Recombinant Flag-tagged hnRNPM was co-pulled down with *in vitro*-synthesized biotin-labelled PLANE as shown in RNA pulldown assays. Data are representatives of 3 independent experiments.

e *In vitro*-synthesized full length (FL) PLANE and PLANE fragment 331-751 but not 1-330 or 752-951 were coprecipitated with hnRNPM as shown in RIP assays. Data are representatives of 3 independent experiments.

f PLANE was co-precipitated with full-length (FL) hnRNPM, hnRNPM Δ RNA recognition motif (RRM) 1 and hnRNPM Δ RRM3 but not hnRNPM Δ RRM2 as shown in RIP assays. Data are representatives of 3 independent experiments.

g Representative microscopic photographs of immunofluorescence staining showing co-localization of hnRNPM and SC35 in A549 cells grown on coverslips. Data shown are representatives of 3 independent experiments. Scale bar: 2 μ m

h hnRNPM was co-precipitated with U1-70K in A549 and H1299 cells. Data are representatives of 3 independent experiments. IP: immunoprecipitation.

Figure 6. PLANE links hnRNPM to regulation of NCOR2 pre-mRNA AS

a hnRNPM was co-pulled down with the NCOR2 pre-mRNA using antisense probes directed to the hnRNPM binding sites (hnRNPM-BSs) at intron 45 in A549 and H1299 cells as shown in RNA pulldown assays. Data are representatives of 3 independent experiments. S, sense; AS, antisense.

b The hnRNPM-BSs at intron 45 of the NCOR2 pre-mRNA was coprecipitated with hnRNPM in A549 and H1299 cells using RIP assays. Data are representatives of 3 independent experiments.

c SiRNA knockdown of hnRNPM enhanced the NCOR2-202-generating AS event in A549 cells. Data are representatives of 3 independent experiments.

d Relative levels of NCOR2-202/-001/-005 in cells with or without hnRNPM knockdown as shown in **c**. Data are representatives of 3 independent experiments.

e Overexpression of hnRNPM reduced the NCOR2-202-generating AS event, which was reversed by co-knockdown of PLANE in A549 cells. Data shown are representatives of 3 independent experiments.

f Relative levels of NCOR2-202/-001/-005 as shown in **e** quantitated using densitometry. Data are representatives of 3 independent experiments.

g Induced knockdown of PLANE decreased the amount of hnRNPM associated with the hnRNPM-BSs at the NCOR2 pre-mRNA, which was reversed by co-overexpression of a shRNA-resistant PLANE mutant (PLANE-R) as shown in RIP assays. Data are representatives of 3 independent experiments.

h PLANE was coprecipitated with a fragment at intron 45 of NCOR2 pre-mRNA containing the PLANE-BR in A549 cells with or without siRNA knockdown of hnRNPM as shown using dChIRP assays. Data are representatives of 3 independent experiments.

i Introduction of a shRNA-resistant PLANE mutant (PLANE-R) but not a PLANE mutant with its fragment 331-751 deleted (PLANE-R- Δ 331-751) or its DFOs deleted (PLANE-R- Δ DFOs) induced the association between hnRNPM and the hnRNPM-BSs at the NCOR2 pre-mRNA in A549.shPLANE cells with induced knockdown of PLANE. Data are representatives of 3 independent experiments.